Premium
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
Author(s) -
Bringhen Sara,
Voorhees Peter M.,
Plesner Torben,
Mellqvist UlfHenrik,
Reeves Brandi,
Sonneveld Pieter,
Byrne Catriona,
Nordström Eva,
Harmenberg Johan,
Obermüller Jakob,
Richardson Paul G.
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17302
Subject(s) - dexamethasone , medicine , multiple myeloma , lenalidomide , refractory (planetary science) , oncology , melphalan , bortezomib , astrobiology , physics
Summary An updated survival analysis was conducted for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46‐month median overall survival (OS) follow‐up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time‐to‐next treatment for melflufen plus dexamethasone was 7·9 months. In summary, melflufen plus dexamethasone resulted in sustained long‐term clinical benefit in patients with RRMM.